Compare NVEC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVEC | MDCX |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.0M | 15.9M |
| IPO Year | 1995 | 2025 |
| Metric | NVEC | MDCX |
|---|---|---|
| Price | $100.55 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 82.3K | ★ 4.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ 0.96 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $26,331,218.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.35 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $57.21 | $0.15 |
| 52 Week High | $135.00 | $3.05 |
| Indicator | NVEC | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 25.61 |
| Support Level | $96.79 | $0.15 |
| Resistance Level | $111.83 | $0.36 |
| Average True Range (ATR) | 3.68 | 0.02 |
| MACD | -0.40 | -0.01 |
| Stochastic Oscillator | 21.84 | 6.18 |
NVE Corp is engaged in developing and selling devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.